Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos’ decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
TCR-T Breakthrough | Adaptimmune's early FDA approval of Tecelra for synovial sarcoma marks a significant milestone in T-cell receptor engineered therapies |
Financial Crossroads | Despite impressive revenue growth, Adaptimmune faces challenges with negative EPS forecasts and a revised cash runway extending into late 2025 |
Market Dynamics | Explore Adaptimmune's pioneering position in the TCR-T market, balanced against the $727,000 list price for Tecelra and potential adoption hurdles |
Future Prospects | Analyst price targets hover around $1.00, reflecting cautious optimism as Adaptimmune navigates commercialization challenges and pipeline development |
Metrics to compare | ADAP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADAPPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −1.8x | −0.5x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | −0.6x | 0.7x | 2.6x | |
Price / LTM Sales | 0.1x | 4.5x | 3.3x | |
Upside (Analyst Target) | - | 329.2% | 43.5% | |
Fair Value Upside | Unlock | 34.8% | 6.8% | Unlock |